Join us as leading experts discuss key data from the Plenary, Late-breaking, EHA Awards and top oral sessions across each major disease area at EHA 2026
touchHEMATOLOGY coverage of EHA 2026
The European Hematology Association (EHA) 2026 Congress brought together the global hematology community to unveil the latest practice-shaping advances in hematological malignancies and blood disorders. From plenary and late-breaking trial results to prestigious award winners, novel therapeutics, translational science and emerging technologies, the meeting delivered a vast volume of data. In this expert-led round-up, leading specialists distil the most important data and key takeaways from across each disease area, offering an essential guide to the studies set to shape the future of hematology.
EHA Award Winners
EHA Lifetime Achievement Award: Prof Claire Harrison reflects on the milestones that shaped her career in MPNs and the importance of mentorship and patient partnership.
→ Read: Prof Claire Harrison on a lifetime in MPNs
EHA Clinical Award: Prof Josep-Maria Ribera reflects on four decades of progress in ALL, the increasing biological complexity of the disease, and why combining immunotherapy with subtype-specific targeted approaches will define the next era of treatment.
→ Read: Prof Josep-Maria Ribera on the evolution of ALL
EHA Research Excellence Award: Prof George Vassiliou reflects on the scientific milestones that shaped his career, from defining clonal haematopoiesis to identifying therapeutic vulnerabilities in AML, and outlines what may come next for prevention-focused hematology.
→ Read: Prof George Vassiliou on his legacy in clonal haematopoiesis
Plenary abstracts
“Tafasitamab plus lenalidomide and R-CHOP is significantly better than R-CHOP for high-risk patients with aggressive lymphoma” Prof Georg Lenz
→ Read: frontMIND marks first major frontline advance over R-CHOP in high-risk DLBCL in decades
“Maybe we should shift our focus from tumor cells to T cells. If we can identify ways to improve T-cell function, that could apply across many different tumor types.” Prof Yizhen Li
→ Read: Could releasing the ‘brake’ on T cells improve bispecific efficacy?
“We are not just adding something new; we are removing something toxic and replacing it with something more effective. The next question is how much further we can reduce chemotherapy. These data are so clear in terms of relapse reduction and toxicity reduction that there is really no alternative.” Prof Martin Schrappe
→ Read: AIEOP-BFM ALL 2017: Can immunotherapy replace chemotherapy in pediatric ALL?
Late-breaking abstracts
“This may mark the beginning of a new era of fixed-duration combination therapy in relapsed CLL” Dr Matthew Davids
→ Read: BRUIN CLL-322 positions fixed-duration pirtobrutinib triplet as potential new standard in relapsed CLL
“CAR-T is not only for malignant disease, it may offer a new therapeutic roadmap for chronic autoimmune hematologic disorders like ITP” Prof Heng Mei
→ Read: BCMA CAR-T shows early promise for immune resetting in refractory primary ITP
“The battle against myeloma is a marathon, so we need as many treatment options as possible, especially when these include novel agents with unique mechanisms of action” Prof Meletios Dimopoulos
→ Read: SUCCESSOR-2 positions MeziKd as a potential new option in lenalidomide- and anti-CD38-exposed RRMM
myelofibrosis
“SENTRY is a landmark study in myelofibrosis. This is proof of principle that we need to move towards new treatment paradigms.” Prof Claire Harrison
→ Read: Phase 3 SENTRY trial positions selinexor plus ruxolitinib as potential new frontline option in myelofibrosis
Acute myeloid leukemia
“Menin inhibitors are poised to make a major change in the AML treatment landscape, particularly as we move into more rational frontline combinations” Dr Amer Zeidan
→ Read: KOMET-007 reinforces frontline potential of ziftomenib in NPM1-mutated and KMT2A-rearranged AML
Transplant-associated thrombotic microangiopathy
“What we now understand is that TA-TMA is not simply another complication of transplantation; it is a distinct thrombotic microangiopathy with unique biological drivers” Dr Eleni Gavriilaki
→ Read: Refining the management of transplant-associated thrombotic microangiopathy
Hematology nursing
“Nurses are no longer only administering treatments; they are key partners in patient education, toxicity monitoring, symptom management, survivorship care and shared decision-making” Erik Aerts, President, Hematology Nurses & Healthcare Professionals Group
→ Read: Inside HNHCP: Building education, recognition and resilience in hematology nursing
New insights are added regularly, covering a broad range of subspecialties and evolving clinical scenarios. Sign up below for Free Access to the latest clinical updates in your specialty!
This content has been developed independently by Touch Medical Media for touchHEMATOLOGY. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Cite: EHA 2026 complete round-up: Discover the most important data across hematology. touchHEMATOLOGY. 2nd July 2026.
Editor: Sophie Nickelson, Editorial Director
